Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Exploring the companies and themes that make up this emerging and exciting new sector
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
New 5-Year Psychedelics Warrants Offer Exciting Leverage Play
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
MindMed inks a new partnership for drug development and expands its pipeline.
Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
MINDCURE Announces Listing of Warrants
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
Texas Would Study Psilocybin And MDMA To Treat PTSD And Depression Under New Bill
A Texas lawmaker introduced a bill on Wednesday that would require the state to study the therapeutic potential of psilocybin, MDMA and ketamine in the treatment of certain mental health conditions.
264 Million Reasons Psychedelic Stocks Have More Room to Grow
There is big money to be made from psychedelic stocks and the companies planning to treat depression will be the winners.
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
Iowa GOP Lawmaker Makes Another Push To Decriminalize Psilocybin Mushrooms
A Republican lawmaker in Iowa is taking another swing at reforming the state’s psychedelics laws, introducing a bill on Tuesday to remove psilocybin from the list of controlled substances.
Magic mushrooms: How long do they stay in your system?
Magic mushrooms, or “shrooms,” are a type of mushroom containing psilocybin, a hallucinogenic compound.